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Abstract
Background: Probiotic bacteria can be used for the prevention and treatment of human inflammatory diseases including
inflammatory bowel diseases (IBD). However, the nature of active components and exact mechanisms of this beneficial
effects have not been fully elucidated. Our aim was to investigate if lysate of probiotic bacterium L. casei DN-114 001 (Lc)
could decrease the severity of intestinal inflammation in a murine model of IBD.
Methodology/Principal Findings: The preventive effect of oral administration of Lc significantly reduces the severity of
acute dextran sulfate sodium (DSS) colitis in BALB/c but not in SCID mice. In order to analyze how this beneficial effect
interferes with well-known phases of intestinal inflammation pathogenesis in vivo and in vitro, we evaluated intestinal
permeability using the FITC-labeled dextran method and analysed tight junction proteins expression by immunofluores-
cence and PCR. We also measured CD4
+FoxP3
+ regulatory T cells proportion by FACS analysis, microbiota composition by
pyrosequencing, and local cytokine production by ELISA. Lc leads to a significant protection against increased intestinal
permeability and barrier dysfunction shown by preserved ZO-1 expression. We found that the Lc treatment increases the
numbers of CD4
+FoxP3
+ regulatory T cells in mesenteric lymph nodes (MLN), decreases production of pro-inflammatory
cytokines TNF-a and IFN-c, and anti-inflammatory IL-10 in Peyer’s patches and large intestine, and changes the gut
microbiota composition. Moreover, Lc treatment prevents lipopolysaccharide-induced TNF-a expression in RAW 264.7 cell
line by down-regulating the NF-kB signaling pathway.
Conclusion/Significance: Our study provided evidence that even non-living probiotic bacteria can prevent the
development of severe forms of intestinal inflammation by strengthening the integrity of intestinal barrier and modulation
of gut microenvironment.
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Introduction
Inflammatory bowel diseases (IBD), such as Crohn’s disease and
ulcerative colitis, are severe chronic inflammatory illnesses of the
gastrointestinal tract. Although their etiology and pathogenesis are
not fully understood, it is generally accepted, that the inflamma-
tion is a result of an aberrant immune response to antigens of
resident gut microbiota in genetically susceptible individuals [1].
Moreover, dysbiosis, an imbalance in the intestinal bacterial
ecosystem, has been found in IBD and linked to its pathogenesis
[2]. It has been suggested that this microbial imbalances and an
aberrant immune response could be restored by oral administra-
tion of certain beneficial bacterial species, probiotics [3].
When administered in adequate amounts, probiotics, defined as
live microorganisms, confer a health benefit to the host [4], and
have been successfully used in treatment of IBD [5]. Using animal
models of IBD, three main mechanisms of how these beneficial
microbes protect from intestinal inflammation have been de-
scribed. A single probiotic bacterium could possess more than one
mechanism depending on its unique specific metabolic activities
and cellular structures [6]. First, probiotics may exclude or inhibit
the growth of certain pathogens [7]; second, they may improve the
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and/or systemic immune response or metabolic functions [9]. The
outcome of probiotic therapy also depends on the stage of the
disease and the overall health status of the patient. Despite of the
generally safe profile of the probiotic therapy, the use of live
microorganisms may lead to severe infections, and therefore
represents considerable risk especially in severely ill patients [10].
There is increasing evidence, that similar beneficial effects could
be achieved with sterile lysates or components isolated from
probiotic or even commensal microbes [11].
Colitis induced by dextran sulfate sodium (DSS) is a well
established and reliable model of IBD because its clinical features
resemble the ulcerative colitis [12]. Acute DSS colitis starts with
epithelial cell barrier dysfunction which causes the antigens from
the gut lumen to enter the lamina propria and stimulate the
immune response. The dysfunction of the epithelial barrier starts
as early as the first day after DSS treatment by gradual decrease in
the tight junction protein ZO-1 production, which in turn leads to
increased gut permeability [13,14]. In the acute phase, DSS-
induced colitis is driven mainly by cells of innate immunity,
because it also occurs in the absence of functional T, B and NK
cells [15]. The functional adaptive immune system, however, plays
an important role in the chronic phase of the inflammation and
might be necessary for its preventive treatment with microbial
antigens [11,16].
The most intensively studied and used probiotic bacteria are
lactobacilli [17,18]. Oral treatment with probiotic bacterium L.
casei DN-114 001 has been found to reduce the duration and
severity of diarrhea and common infectious diseases in children
[19]. Moreover, supernatant of this probiotic strain was described
to exert immunological activities and strong inhibitory effect on
epithelial cell adhesion of virulent E. coli strain [20] . These studies
clearly show the beneficial potential of this bacterium, however,
the clinical utility of such approach remains controversial, as
neither the specific mechanisms of action nor the active
component responsible for its beneficial properties has been
established.
In our previous study, we have shown that the preventive
treatment with live probiotic bacterium L. casei DN-114001
protects mice from subsequent acute DSS-induced colitis in
BALB/c mice [21]. Here, we show that oral treatment with lysate
of this bacterium (Lc) has a similar effect, and that this effect is
associated with change in the intestinal microbiota composition,
modulation of mucosal immune system, and induction of
regulatory T cells in mesenteric lymph nodes (MLN). Our results
show that even killed probiotic bacteria can decrease the severity
of the intestinal inflammation, which represents safer and more
practical therapeutic intervention than the use of live bacteria in
the treatment of intestinal inflammation.
Materials and Methods
Preparation of bacteria
Lactobacillus casei DN-114 001 (Danone Institute, Palaiseau
Cedex, France), Lactobacillus plantarum CCDM 185 (Culture
Collection of Dairy Microorganisms, Milcom a.s., Prague), were
grown in an anaerobic chamber in De Man, Rogosa, and Sharpe
broth (Oxoid, Basingstoke, UK) at 37uC until the cultures were in
the late log phase of growth. Both lactobacilli were harvested by
centrifugation (40006 g, 30 min) and washed twice with sterile
phosphate-buffered saline (PBS). After the treatment with the
French press, lactobacilli were freeze-dried and diluted to a
working concentration of 30 g/l. In order to kill all remaining
viable bacteria, the lysate was heated to 60uC for 30 min and the
sterility of all components was verified by both aerobic and
anaerobic 48 hours cultivation before administration.
Animals
Ethics statement: All animal experiments were approved by the
Animal Care and Use Committee of the Institute of Microbiology,
Academy of Sciences of the Czech Republic, approval ID: 10/
2005, 94/2008 and 211/2009. Female BALB/c mice (8–12 weeks
old) or severe combined immunodeficient mice BALB/cJHanHsd-
SCID (SCID) were obtained from a breeding colony at the
Institute of Physiology (Academy of Sciences of the Czech
Republic, Prague, Czech Republic) or at the Institute of
Microbiology (Academy of Sciences of the Czech Republic, Novy
Hradek, Czech Republic), respectively, and reared under
conventional conditions.
Study design and DSS induced colitis
We administered 1.5 mg of Lc in 50 ml of sterile PBS, i.e.
6610
8 CFU of heat killed bacteria, by gavage. To reduce
proteolytic activity in the gut, the Lc components were co-
administered with 1 mg of soybean trypsin inhibitor (Sigma-
Aldrich, St. Louis, MO, USA) dissolved in 50 ml of 0.15 M sodium
bicarbonate buffer (pH 8.0). Control mice were given only sterile
PBS with soybean trypsin inhibitor in bicarbonate buffer. The
administration of lysates was repeated every 7 days for a total
number of 4 doses (on days 0, 7, 14 and 21). Acute colitis was
induced 7 days later by 3% (wt/v) DSS (molecular weight 36–
50 kDa; MP Biomedicals, Irvine, CA, USA) dissolved in tap water
for 7 days, and on the last day of the experiment the colitis was
evaluated by using a clinical activity score, colon length, and the
histological scoring system as described previously [11]. Further-
more, to analyze if the protective effect of Lc could be achieved
also by parenteral administration, four subcutaneus doses of Lc or
PBS (25 mg per dose) were injected in incomplete Freund’s
adjuvant (Difco Laboratories, Detroit, MI, USA) before colitis
induction. For chronic colitis, mice received four cycles of DSS as
described previously [12].
Evaluation of intestinal barrier function
Intestinal permeability in vivo. The intestinal permeability
was measured by determining the amount of FITC-dextran in
blood after it was orally administered as described previously [22].
Briefly, each mouse received 440 mg/kg of body weight of FITC-
dextran (molecular weight 4.4 kDa; Sigma-Aldrich) by gavage. A
blood sample, obtained 5 h later, was first centrifuged (3,000 rpm
at 4uC) for 30 min, and serum was collected and added to a 96-
well microplate. The concentration of FITC-dextran was
determined by spectrophotofluorometry (Safire
2, Tecan Group
Ltd., Ma ¨nnedorf, Switzerland) with an excitation wavelength of
483 nm and an emission wavelength of 525 nm using serially
diluted samples of the marker as standard.
Immunohistology. Segments of colon and terminal ileum
were frozen in liquid nitrogen immediately after removal and stored
at 280uC until used. Frozen sections (6 mm) were mounted on the
poly-L-lysine-coated slides. Then the slides were dried and fixed in
4% buffered paraformaldehyde (pH 7.4) for 10 min at room
temperature. Fixed sections were washed in PBS and blocked with
2% donkey serum (Sigma-Aldrich) in PBS for 20 min at room
temperature. The slides were incubated with the rabbit polyclonal
anti-mouse ZO-1 or occludin antibodies (both from Invitrogen,
Camarillo, CA, USA) overnight at 4uC .T h en e g a t i v ec o n t r o l sw e r e
performed similarly using 1% bovine serum albumin (BSA) in PBS
instead of primary antibody. After washing, the sections were
incubated with donkey anti-rabbit antibody conjugated either with
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ImmunoResearch Laboratories, West Grove, USA). Nuclei were
counterstained using DAPI (49,6-diamidino-2-phenylindole; Sigma-
Aldrich) stain. Finally, the sections were mounted in Vectashield
mounting medium for fluorescence (Vector Laboratories,
Burlingame, CA, USA) and viewed with a fluorescence microscope
Olympus AX-70 (Olympus, Tokyo, Japan).
Determination of ZO-1 mRNA expression in intestinal
tissue. Intestinal mucosa from terminal ileum and colon was
placed in RNAlater stabilization reagent (QIAGEN GmbH,
Hilden, Germany). Total messenger RNA (mRNA) was extracted
by using the RNeasy Mini isolation kit (QIAGEN GmbH)
following the manufacturer’s instructions. RNA integrity was
determined by gel electrophoresis in 1.5% agarose gel stained
with ethidium bromide. The purity of the RNA was assessed by
the ratio of absorbance at 260 and 280 nm. RNA purity was
within a range of 2.0–2.1. The total RNA concentration was
estimated by spectrophotometric measurements at 260 nm
assuming that 40 mg of RNA per mililitre equal one
absorbance unit. Real time PCR was performed as described
previously [23]. Briefly, RNA was converted to cDNA using
Taq-Man reverse transcription reagents (Applied Biosystems,
Foster City, CA, USA). Beta-actin was used as an endogenous
control and its expression was similar in all tested samples. A
reaction mix for real-time PCR was made with Taq-Man
Universal PCR master mix, water, and assays on demand gene
expression products for ZO-1 and b-actin (all Applied
Biosystems, Foster City, CA, USA). The master mix (20 ml)
was aliquoted to the wells on a real-time PCR plate; and each
sample was analyzed in duplicate. A volume of 5 mlo fc D N Aw a s
added to each well, and the PCR reaction was run on a 7300
real-time PCR System (Applied Biosystems, Foster City, CA,
USA) using standard conditions. The data was analyzed with
Genex software (version 4.3.8).
Production of cytokines
Intestinal tissue culture and measurement of
cytokines. Sections of Peyer’s patches (PP), ileum, cecum, and
colon were taken from every mouse. The intestines were then
opened longitudinally, washed in ice cold PBS containing
antibiotics and cultivated for 48 hours at 37uC and 5% CO2 in
complete RPMI medium with 10% fetal bovine serum (Biochrom
AG, Berlin, Germany) and 100,000 U/l penicillin, 100 mg/l
streptomycin (Sigma-Aldrich), as described previously [11] .
Commercially available ELISA sets were used to measure the
levels of TNF-a, IFN-c, TGF-b, IL-10 (Invitrogen Corp.) and IL-6
(R&D Systems Inc., Minneapolis, MN, USA) in these
supernatants. All tests were performed according to the
manufacturers’ recommendations.
Determination of cytokine mRNA expression in intestinal
tissue. The samples were processed as described above (see
Determination of ZO-1 mRNA expression in intestinal tissue).
Gene expression assays for IL-10, IL-6, TNF-a and b-actin were
all purchased by Applied Biosystems, Foster City, CA, USA.
Determination of specific antibodies
Sera and small intestine washings were collected for specific
antibody evaluation. Gut washings were obtained by flushing the
content of isolated small intestine with 2 ml of sterile PBS
containing a mixture of proteinase inhibitors (Sigma-Aldrich). The
samples were then vortexed and centrifuged at 4uC, and the
supernatant was collected and stored at 280uC until analysis.
Indirect ELISA, optimized in our laboratory as previously
described [11], was used to assess the specific antibody response
against Lc in serum (IgG, IgM, and IgA) and gut washings
(secretory IgA; SIgA). Briefly, Nunc MaxiSorp 96-well plates
(Thermo Fisher Scientific Inc., Rochester, NY, USA) were coated
overnight with Lc (100 ml/well at 10 mg/l in PBS) and blocked
with 1% BSA (Sigma-Aldrich) in PBS. Serum and gut washing
samples diluted 1:50 and 1:10 in 1% BSA, respectively, were
added and incubated for 2 hours. As control sera normal reference
serum purchased from Bethyl Laboratories (TX, USA) and
hyperimmune serum prepared by four subcutaneous injections
of Lc in incomplete Freund’s adjuvant within 14 days intervals
(50 mg of Lc in the each dose) were used. After washings (three
times with PBS containing 0.05% Tween 20 (Sigma-Aldrich)),
secondary antibodies (50 ml/well) were added and incubated for
1 hour at room temperature. Antibody combinations were used as
follows: 1) rabbit anti-mouse SIgA (Uscn Life Science Inc., China)
and horseradish peroxidase (HRP)-labeled anti-rabbit IgG (Cell
Signaling Technology Inc., Danvers, MA, USA); 2) biotinylated
anti-mouse IgA (Sigma-Aldrich) and streptavidin-HRP (R&D
Systems Inc.); 3) HRP-labeled anti-mouse IgG; 4) HRP-labeled
anti-mouse IgM (both The Binding Site Ltd, Birmingham, UK).
All reagents were diluted in 1% BSA in PBS except anti-IgA
antibody that was diluted in 1% BSA with 5% fetal bovine serum
(BioClot GmbH, Aidenbach, Germany). The plates were devel-
oped with 3,39,5,59-tetramethylbenzidine (Sigma-Aldrich) and the
optical density (OD) was measured at 450 nm. The OD of the
background (1% BSA) was subtracted and resulting adjusted ODs
of the treated groups were compared with those of PBS-treated
groups.
Flow cytometry
Single-cell suspensions of spleens, MLNs and PPs were prepared
and stained for Tregs using FoxP3 Staining Set (eBioscience, San
Diego, CA, USA) with fluorochrome-labeled anti-mouse mAbs:
CD4-QdotH 605 (Invitrogen, Carlsbad, CA, USA), CD8-BD
Horizon
TM V500 (BD Biosciences, San Jose, CA, USA), CD3-
FITC and FoxP3-Phycoerythrin (both from eBioscience) accord-
ing to the manufacturer’s recommendation.
RAW 264.7 cells were cultivated and stained for IL-7R-
Alexa647 (a gift from Pavel Otahal, IMG AS CR, Prague, Czech
Republic), CD206-PE (AbD Serotec, Oxford, UK), CD-11c-
NC625 and F4/80-APC780 (both from eBioscience). Hoechst
33342 (Sigma-Aldrich) was used to determine cell viability. Flow
cytometric analysis was performed on LSRII (BD Biosciences),
and the data was analyzed using FlowJo software (Tree Star Inc.,
Ashland, OR, USA).
Evaluation of the anti-inflammatory properties of Lc in
vitro
The LPS-activated macrophage cell line (RAW 264.7; ATCC
TIB-71) was cultivated in the presence of different concentrations
of bacterial lysate, as previously described [11]. Briefly, the cells
were cultured for 24 hour at 37uC and 5% CO2 in Dulbecco’s
modified Eagle’s medium (Institute of Molecular Genetics AS CR,
Prague, Czech Republic) containing 10% heat-inactivated fetal
bovine serum (Biochrom AG), 4.5 g/l glucose, 1.5 g/l sodium
bicarbonate, 4 mM glutamine (Institute of Molecular Genetics AS
CR), 100,000 U/l penicillin and 100 mg/l streptomycin (both
Sigma-Aldrich). The cells were cultured together with Lc, lysate of
L. plantarum (Lp) or sterile PBS in the presence or absence of LPS
(Salmonella typhimurium, 1 mg/l, Sigma-Aldrich). After cultivation,
the concentration of TNF-a in the supernatant was measured with
ELISA (Invitrogen). The nuclear proteins were extracted from
stimulated RAW264.7 cells by a nuclear extract kit (Active Motif,
Rixensart, Belgium) and used to quantify the DNA binding activity
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factor assay kit (Active Motif). In NF-kB assay, only the
concentration with the strongest immunomodulatory properties
of Lc was used, i.e. 10 pg/l. All assays were performed according
to the manufacturer’s recommendation.
Evaluation of microbiota changes by pyrosequencing
Stool samples from PBS or Lc-treated mice, on day 0, 28 (just
before DSS administration) and 35 (the last day of experiment)
were collected. Total DNA from these samples was then isolated
with ZR Fecal DNA Kit
TM (Zymo Research Corp., Orange, CA)
according to the manufacturer’s recommendation.
DNA was subsequently gel-purified and PCR was performed in
triplicate for each primer pair, and pooled to minimize random
PCR bias. The reaction mixture contained 1 ml of DNA (10 ng/
ml), 1.5 mmol/l MgCl2, 0.2 mmol/l of dNTPs, 16 PCR buffer
and 1 U platinum TAQ DNA polymerase (Invitrogen) and
0.40 mmol/l of forward modified primer consisting of 454 adaptor
A( 5 9-CCATCTCATCCCTGCGTGTCTCCGACTCAG-39;
Genome Sequencer FLX system), unique 10-base tag sequence
(ATATCGCGAG, CGTGTCTCTA, CTCGCGTGTC, TAG-
TATCAGC, TCTCTATGCG) and universal broad-range bac-
terial primer 59-AYTGGGYDTAAAGNG and 0.40 mmol/l of
reverse primer consisting of adaptor B (59-CCATCT-
CATCCCTGCGTGTCTCCGACTCAG-39) and universal
primer TACNVGGGTATCTAATCC. PCR conditions were as
follows: 16:9 5 uC, 3 min; 356:9 4 uC, 50 sec; 40uC, 30 sec; 72uC,
60 sec; 16:7 2 uC, 5 min and final hold at 4uC. The length of PCR
product was checked on the agarose gel electrophoresis. PCR
product was subsequently purified using magnetic beads (AMPure
beads, Beckman Coulter Genomics, Danvers, USA). Concentra-
tion was measured on Qubit fluorometer (Invitrogen, Carlsbad,
CA, USA). Equimolar amounts of PCR product from each sample
were used for unidirectional 454 FLX amplicon pyrosequencing
using LIB-L emPCR kits following the manufacturer’s protocols
(Roche Diagnostics, Basel, Switzerland).
Metagenomic data processing
Flowgrams were processed using amplicon analysis option in
data processing software from Roche. The sequencing resulted in
161551 overall number of reads. Quality trimmed sequences
obtained from the FLX sequencing run were processed using RDP
pyrosequencing pipeline. Beforehand, data files were depleted of
chimeras by Black Box chimera Checker [24] using default
settings. Processing involved aligning of sequences with fast,
secondary-structure aware Infernal aligner, subsequent clustering
with max distance of 3% based on complete-linkage clustering
method and classifying of incurred clusters by naı ¨ve Bayesian
rDNA classifier [25]. Bootstrap cutoff was set to 50%, which was
sufficient for accurate classification at the genus level. Generated
designations of clustered sequences together with their relative
abundances within the given samples were used for comparing
bacterial diversity.
Statistical analysis
One-way analysis of variance (ANOVA) with Dennett’s multiple
comparison test was used to compare multiple experimental
groups with the control group. Differences between two groups
were evaluated using an unpaired two-tailed Student’s t-test and
deviation of values from hypothetical mean were calculated by one
sample t-test. The data is presented as the mean 6 standard
deviation (SD) unless stated otherwise and differences were
considered statistically significant at P#0.05. GraphPad Prism
statistical software (version 5.0, GraphPad Software, Inc., La Jolla,
CA,USA) was used for analyses.
Results
Oral administration of lysate L. casei attenuate the acute
colitis in BALB/c mice but not in SCID mice
In our previous study we showed that oral treatment with L. casei
DN-114 001 attenuates the severity of acute experimental colitis
[21]. To test if its lysate have similar activity, we pretreated mice
with four weekly oral doses of Lc and induced colitis by DSS in
BALB/c and SCID mice. Oral (Table 1A) but not parenteral (data
not shown) administration of Lc is effective in preventing the acute
DSS colitis in BALB/c mice, improving clinical and morpholog-
ical markers of colitis. In contrast, when colitis was induced in
SCID mice (Table 1A) pretreatment with Lc failed to improve
acute colitis in all tested parameters. Also no significant effects of
Lc were found when the model of chronic colitis was used (data
not shown).
Lysate of L. casei prevents the increase in intestinal
permeability and preserves ZO-1 expression in acute
colitis
Increased intestinal permeability caused by impairment of the gut
barrier function drives the pathogenesis of intestinal inflammation in
both DSS-induced colitis and human IBD [26,27]. To investigate the
effect of Lc on the gut barrier function in acute DSS-induced colitis,
we administered a single dose of FITC–dextran by gavage and
measured the intensity of fluorescence in mouse serum 5 h later. Oral
pretreatment with Lc significantly decreased the intestinal perme-
ability to macromolecules on the last day of DSS (day 35) to the same
extent as found in healthy mice (Figure 1A). One possible mechanism
by which this effect could be mediated is the reinforcement of tight
junctions. Previous studies have demonstrated that DSS causes the
extensive decrease in ZO-1 expression and occludin redistribution
and that this effect could be prevented by live bacteria or their
components in the murine colonic epithelium [28,29]. Therefore, we
Table 1. Lc improves the severity of DSS-induced colitis in BALB/c, but not in SCID mice.
Mouse strain Experimental group Disease activity index Colon length (cm) Histological grade
BALB/c DSS/PBS 2.8060.68 6.3560.62 1.5960.54
DSS/Lc 1.6761.09*** 7.1460.34*** 1.2060.51*
SCID DSS/PBS 1.9561.66 6.6360.55 1.260,84
DSS/Lc 1.9961.54 7.1761.21 1.2660.85
Values are expressed as means 6 SD (5 BALB/c mice per group) of one representative experiment out of three independent experiments. Unpaired Student’s t-test in
BALB/c mice was used to evaluate the significance of differences between experimental groups and the PBS-treated control group (*P,0.05, ***P,0.001).
doi:10.1371/journal.pone.0027961.t001
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PLoS ONE | www.plosone.org 4 November 2011 | Volume 6 | Issue 11 | e27961Figure 1. Oral treatment with Lc strengthens the gut barrier function as compared to PBS control mice. (A) Measurement of intestinal
permeability by FITC-dextran. Serum levels of 4.4-kDa FITC-dextran 5 hour after administration by gavage in DSS/PBS, DSS/Lc-treated group and
healthy controls. Immunohistological detection of tight junction proteins ZO-1 (B) and occludin (C) in representative sections of colon and terminal
ileum from DSS/PBS-, DSS/Lc-treated group and healthy controls. Fluorescent signal of ZO-1 or occludin (red) is merged with DAPI counterstained
nuclei (blue). mRNA expression of ZO-1(D) and occludin (E) evaluated in DSS/PBS, DSS/Lc treated group and healthy controls in colon and terminal
ileum. RT-PCR was performed using TaqManH gene expression assay for ZO-1. b-actin was used as the internal control. One-way ANOVA with
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tight junction proteins production and distribution. As shown by
immunohistochemistry and RT-PCR, treatment with Lc could
completely prevent the loss of expression and changes in distribution
of ZO-1 in both colon and terminal ileum (Figure 1B and D).
Interestingly, in PBS-treated mice with subsequent induction of colitis
(DSS/PBS) or in Lc-treated mice with subsequent induction of colitis
(DSS/Lc) was a substantial loss of occludin in colon but not in
terminal ileum (Figure 1C and E). Nevertheless, its distribution in
colon seems to be slightly less affected in DSS/Lc- as compared with
DSS/PBS-treated mice. Thus, we are able to demonstrate that the
expression of ZO-1 in the colon and terminal ileum was significantly
preserved following Lc treatment and probably contributes to
reduced permeability of FITC-dextran. These findings suggest that
treatment with Lc enhances the intestinal barrier function.
Oral treatment with lysate of L. casei results in important
changes in the gut microbial ecology
Changes in the intestinal gut microbial ecology are expected
to be associated with the state of disease and could be influenced
by probiotic treatment [30]. To determine the impact of oral
treatment with Lc on the intestinal microbiota, we used
pyrosequencing of segments of genes for bacterial 16S rRNA.
We collected feces before the treatment (day 0), before the colitis
induction (day 28), and at the end of the experiment (day 35).
We found that oral treatment with Lc resulted in significant
changes in the intestinal microbial ecology (Figure 2). The
frequently present genus in our fecal samples was a little-studied
genus Barnesiella, from the Bacteroidetes phylum, one of the most
abundant phylum in intestinal microbiota. The next most
abundant genus with very well described capability to ameliorate
intestinal inflammation Lactobacillus increased in abundance after
exposure to DSS and the Lc treatment. This increase in
abundance was not observed in the control PBS group. The
Bacteroides, known to be increased during DSS-induced colitis,
proliferated after intestinal inflammation, was induced in Lc and
PBS treated groups. Moreover, there is an increase in the biggest
group of genera from Clostridium cluster: butyrate producing
Butyricicoccus, Coprococcus and Anaerostipes. Butyrate is crucial for
energy homeostasis of mammalian colonocytes, capable to
prevent their autophagy [31]. Dynamic changes in microbiota
composition were observed before and during DSS administra-
tion in both Lc-treated and PBS-treated control group.
Therefore, we can suggest that these microbial changes lead to
improvement in gut barrier function and decrease susceptibility
to intestinal inflammation by producing active substances such as
lactate and butyrate.
Oral administration of Lc changes the immune response
of gut mucosa
Changes in cytokine microenvironment in the gut mucosa can
influence the mucosal immune response to luminal antigens
leading to the decrease of intestinal inflammation. Therefore, we
investigated if the protective effect of Lc is associated with
modifications in inflammatory response in the key compartments
of the gut. We cultivated tissues from four distinct parts of the gut
of either DSS/PBS or DSS/Lc-treated mice for 48 h and then
measured the cytokines in supernatants by ELISA. We found that
pretreatment with DSS/Lc decreased the production of pro-
inflammatory cytokines (IL-6, IFN-c) and anti-inflammatory
cytokine IL-10 in PPs, cecum and colon as compared to DSS/
PBS-treated mice (Figure 3). These results were confirmed at
mRNA level by RT-PCR (data not shown).
Lc treatment increased the number of regulatory T cells
Since the intestinal inflammation in acute DSS-induced colitis is
triggered by microbial antigens [32], the induction of oral
tolerance to microbiota could be the one of the potential
mechanisms of Lc protective effects. As the oral tolerance is
maintained mainly at the periphery by Tregs , we analyzed the
changes in CD4
+FoxP3
+ Tregs in the spleen, MLNs and PPs of
DSS/PBS-, DSS/Lc-treated mice. We found a statistically
significant increase in Tregs in MLN of DSS/Lc-treated mice as
compared to DSS/PBS-treated mice. There were no statistically
significant differences in the numbers of Tregs in spleen and PPs
between these groups (Figure 4).
Lysate of L. casei, but not L. plantarum, decreases the
production of TNF-a and down-regulates NF-kB activity
in LPS-activated macrophages
Because probiotics have an immunomodulatory effect on cells
involved in innate immunity [33] and because the macrophages
play a role in the pathogenesis of DSS-induced colitis [12], we
analyzed the anti-inflammatory effect of Lc in LPS-activated
macrophages in vitro. We found that doses below 100 pg/l
significantly decrease the production of TNF-a by LPS-stimulated
RAW 264.7 cells in vitro, while similarly prepared Lp did not
(Figure 5A). Using the FACS analysis of cultured cells, we found
that neither Lc nor Lp changes the viability of RAW 264.7 cells
(data not shown). The treatment with either lysate of bacteria in
the absence of LPS did not change the TNF-a production (data
not shown), this data is in agreement with a study using L. casei
3260 [34]. As published by others [34,35], this result suggests that
Lc could interfere with the intracellular proinflammatory signaling
cascade leading to activation of NF-kB transcription factor. To test
this hypothesis, we isolated the nuclear extract from the untreated
RAW 264.7 cells or from cells treated with either LPS (1 mg/l), or
LPS with Lc and measured the activity of the NF-kB signaling
pathway. Lc significantly decreased the NF-kB/DNA binding
activity of p65 subunit as compared to the LPS-only or Lp+LPS
treated cells (Figure 5B).
Since Lc treatment decreased production of TNF-a by LPS-
activated macrophages, we decided to characterize macrophages
further by investigating their stage of polarization by FACS. We
found that M2 phenotype marker, the mannose receptor CD206
was significantly upregulated and M1 phenotype marker IL-7R
downregulated in LPS+Lc treated macrophages as compared to
either LPS or LPS+Lp treated macrophages. Therefore, Lc seems
to counteract the LPS mediated M1 polarization. Neither Lc nor
Lp without the addition of LPS changes the macrophage
polarization.
Discussion
Oral treatment with probiotic bacteria has emerged recently as
a potentially useful therapeutic strategy for human IBD [5,36].
However, the clinical utility of such approach remains controver-
Dunnett’s multiple comparison test was used to evaluate the significance of differences between experimental groups and the DSS/PBS-treated
control group (*P,0.05, **P,0.01, ***P,0.001). Data represent means (bar) 6 SD (whisker) of five mice of one representative experiment out of
three independent experiments. Scale bars are 10 mm in ZO-1 and 20 mm in occludin figures.
doi:10.1371/journal.pone.0027961.g001
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therapeutic effects of specific bacterium has been difficult to
establish. We have shown previously that repeated oral adminis-
tration of probiotic bacteria L. casei DN-114 001 protects BALB/c
mice from severe forms of acute intestinal inflammation [21]. In
this study we demonstrated that not only live probiotic bacteria,
but also its lysate protects BALB/c, but not SCID, mice from
severe forms of DSS-induced inflammation.
The lack of protective effect in SCID mice suggests that
mechanisms of adaptive immunity are essential for the beneficial
effect of Lc. We did not find any changes neither in Lc-specific
serum IgA, IgG and IgM, nor in gut SIgA during our experiments
(data not shown), so we analyzed another mechanism executed by
adaptive immune response, oral tolerance. Major role in this
mechanism is played by Tregs, whose protective role in
inflammation control has been clearly established [37]. In this
study, we found that Lc treatment leads to significant increase in
Tregs in MLNs, but not PPs. This might be because MLNs are
crossroads between mucosal and systemic immunity, because even
naı ¨ve T cells (L-selectin expressing cells) can enter and after the
Figure 2. Oral treatment with Lc changes the intestinal microbiota composition. Normalized and z scored heat map and clustering
dendrogram comparing relative abundance of the top 50 most abundant bacterial species in fecal microbiota of PBS (pool of 5 mice) and Lc-treated
mice (pool of 5 mice) before the treatment (Day 0), before colitis induction (Day 28) and at the end of the experiment (Day 35). Horizontal columns
represent the day of the experiment and or the treatment; vertical rows depict genus sorted from the most abundant species from left to right. The
color scale for the heat maps is shown in upper left corner. The samples were clustered on the basis of their similarity by unsupervised clustering in
the package CLUTO 2.1.1 (http://glaros.dtc.umn.edu/gkhome/cluto/cluto/download), as described previously [56].
doi:10.1371/journal.pone.0027961.g002
Figure 3. Pretreatment with Lc changes cytokine production in different parts of the gut. After DSS treatment and 24 hours cultivation,
the production of cytokines TNF-a, TGF-b, IL-6, IL-10, IFN-c differs in various parts of the gut as measured by ELISA. *P,0.05, **P,0.01 between DSS/
PBS and DSS/Lc-treated mice in the same part of the gut was compared by unpaired Student’s t-test (n=10 per group).
doi:10.1371/journal.pone.0027961.g003
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+FoxP3
+ Tregs in MLNs. No significant changes were found in spleen or
Peyer’s patches. The plots shows the expression of CD4 versus FoxP3 on gated Th cells (CD3
+CD8
2), and the values within the plots represent the
mean 6 standard deviation of the total numbers of CD4
+FoxP3
+ T cells from one representative experiment out of three independent experiments
(3–5 mice per group). One-way ANOVA with Dunnett’s multiple comparison test was used to evaluate the significance of differences in numbers of
CD3
+CD8
2CD4
+FoxP3
+ cells between DSS/Lc-treated groups and the DSS/PBS-treated (control) group (*P,0.05).
doi:10.1371/journal.pone.0027961.g004
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cells) from intestine became Tregs [38].
The intestinal barrier prevents viable enteric bacteria and the
microbiota derived components from excessive interaction with
the immune system. Here, we demonstrated that increase in
intestinal permeability and the decrease in local ZO-1 expression,
typical for DSS-treated mice, are both significantly improved by
oral application of Lc. These results are in agreement with several
studies showing that L. casei and other probiotics can strengthen
the gut barrier function [28,39]. Probiotic E. coli Nissle 1917
provided protection against DSS-mediated leakiness and was
capable to produce specific up-regulation of ZO-1 expression in
the intestinal epithelial barrier [29]. In addition, treatment with
probiotic mixture VSL#3, where one of included bacterial strain
is L. casei, prevents changes in expression and distribution of tight
junction proteins ZO-1 and occludin [40]. It is well known that
inadequate function of intestinal barrier could lead to inflamma-
tory and neoplastic diseases [41,42]. The disruption of the gut
barrier has been identified as one of the crucial steps in IBD
pathogenesis, causing excessive host-microbiota interaction during
the initial phases of the IBD [26]. Protection of the gut barrier
from disruption by induction of changes in expression and
distribution of tight junction proteins and mucus was proposed
as a key mechanism of probiotic function [29,43].
Several studies showed that there is a marked difference in the gut
microbiota composition in IBD patients (‘‘dysbiosis’’) as compared to
healthy individuals. These changes in microbiota composition, or
presence of certain microbial species with increased virulence, cause or
perpetuate the intestinal inflammation in IBD [44]. Here, we report
that oral treatment with Lc significantly changes the composition of gut
Figure 5. Lc exerts anti-inflammatory effect on LPS-activated macrophage cell line RAW 264.7. (A) Lc decreases the production of TNF-a
in LPS-activated macrophages while Lp does not. TNF-a production by cells stimulated with 1 mg/l of LPS is set as 100% and data are expressed as
means 6 standard error of the mean of three independent experiments. *P,0.05: the means were compared against a hypothetical mean of 100%
by one sample t-test (B) The effect of Lc on NF-kB binding activity in LPS-stimulated RAW 264.7 cells. Lc and Lp was co-cultured with LPS-activated
cells for 24 h, and then the binding activity of NF-kB subunit p65 was analyzed by colorimetric assay. Data are expressed as mean 6 standard
deviation of three independent experiments. One-way ANOVA with Dunnett’s multiple comparison test was used to evaluate the significance of
differences between experimental groups and the LPS-treated cells group (**P,0.01, ***P,0.001). (C, D) Lc counteracts the LPS mediated M1
polarization. Expression of F4/80, CD206, IL-7R was determined by flow cytometry. One-way ANOVA with Dunnett’s multiple comparison test was
used to evaluate the significance of differences between experimental groups and the LPS-treated cells group (**P,0.01).
doi:10.1371/journal.pone.0027961.g005
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involved in the probiotics-mediated protection from intestinal
inflammation [29,45]. Some of them are attributed to the fact, that
probiotics can grow and colonize the gut, which could not be achieved
with the non-living bacteria. The clear protective effect of bacterial
lysate administration in intestinal inflammation is, therefore, rather
indirect by shaping the gut microbial community or influencing the
immune response. Nevertheless, similar mechanisms as in live bacteria
could be involved to explain this effectiveness. Probiotics (or certain
bacteria in general) can produce substances with antibiotic properties,
such as bacteriocins, and molecules capable to signal to other members
of the ecosystem to adjust their growth (quorum sensing modifiers), as
recently reviewed [46]. These molecules could be present in the lysates
of bacteria and, selectively modify the bacterial populations [47].
Moreover, certain probiotics can induce long-term production of anti-
microbial peptides in vivo, which can shape the gut microbiota
composition long time after the probiotic therapy has ended [48].
These mechanisms cause more favorable microbiota composition thus
renders the Lc-treated mice less susceptible to intestinal inflammation.
By using the pyrosequencing technique we observed an increase
in Bacteroides genus after induction of intestinal inflammation as
shown previously [11]. DSS/Lc compared to DSS/PBS-treated
group has shown a substantial increase in Lactobacillus genus which
suggests that treatment with Lc promotes this genus among others.
This effect could be caused by formation of niche ideal to
lactobacilli. These and other differences in microbiota could be
also explained by decreased inflammation in Lc-treated mice
mediated by differing immunological mechanisms.
The cytokines produced in the gut mucosa greatly influence the
resulting immunological outcome. The production of anti-
inflammatory cytokines induces the mucosal unresponsiveness
and tolerance and high levels of pro-inflammatory cytokines
induce protective immune response and inflammation [49]. Here,
we report that Lc treatment decrease the production of pro-
inflammatory cytokines IL-6 and IFN-c as well as anti-inflamma-
tory cytokine IL-10 in both PP and the large intestine. This
suggests that Lc can influence both the induction and effectors’
functions of the mucosal immune system. We did not find
significant decrease in local production of TNF-a, despite the clear
differences in the colitis severity between Lc/DSS and PBS/DSS
treated mice. This is consistent with our previous experiments,
[11] and suggests that, despite being crucial pro-inflammatory
cytokine produced by macrophages, TNF-a could be either
exhausted or downregulated by IL-10, cytokine inhibiting TNF-a
production, at this stage of colitis. Interestingly, since IFN-c
increases the gut permeability [50], a decrease in its local
production can be responsible for strengthening of the gut barrier
function as we found in Lc-treated mice. This is in agreement with
findings that live L. casei can downregulate the pro-inflammatory
mediators in the lamina propria of inflamed mucosa from Crohn’s
disease patients during ex vivo cultivation [51]. However, various
strains of lactobacilli could differ in their immunological activities
[52], and some lactobacilli are capable to induce T cells toward
Th1 [53] or Th2 [54] immune responses.
Acute DSS colitis is believed to be driven initially by innate
immunity mechanisms and, in particular, the role of macrophages
has been proposed [12,15,32]. Therefore we tested the ability of
bacterial lysates to decrease the inflammatory response of LPS-
activated macrophages in vitro. We found that Lc, but not Lp,
decreases the production of TNF-a, and the activation of NF-kB
cascade and polarizes macrophages to M2 phenotype, suggesting a
possible direct effect of Lc on the cells of the innate immunity. It is
not excluded that negative regulators are involved in beneficial
anti-inflammatory effects of probiotics [55].
In conclusion, our data provide evidence that even lysate of L. casei
DN-114 001 can protect from induction of intestinal inflammation,
thus confer a health benefit for the host. This is achieved by
mechanisms that comprise: a) improvement in the gut barrier function,
b) correction of the dysbiosis, and c) modulation of the mucosal
immune response. These complex immunomodulatory properties of
bacterial lysates may lead to the development of new therapeutic
approaches for treatment of chronic intestinal inflammation. More-
over, oral administration of sterile bacteria, in contrast to live bacteria,
may be safer in severely ill or immunocompromised patients.
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